Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 3/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214943 | 0.88 | SCD (0.51) | SCDSLC5A2 | |
| SCHEMBL216737 | 0.81 | KCNN4 (0.45) | PTGDR2FAAHSLC5A2 | |
| SCHEMBL407427 | 0.77 | SMN1; SMN2 (0.45) | PTGDR2LMNAHTTMAPTSLC5A2 | |
| SCHEMBL216751 | 0.77 | SLC5A2 (0.40) | SCDPTGDR2LMNAHTTMAPT | |
| SCHEMBL216192 | 0.74 | PTGDR2 (0.46) | SCDPTGDR2LMNAHTTMAPT | |
| SCHEMBL13004812 | 0.73 | KDR (0.71) | SCDKDRLMNAHTTMAPT | |
| SCHEMBL1023273 | 0.72 | SCD (0.61) | SCDFAAH | |
| SCHEMBL2318169 | 0.71 | SCD (1.00) | SCDMAPT | |
| SCHEMBL216937 | 0.70 | SMN1; SMN2 (0.47) | SCDPTGDR2LMNAHTTMAPT | |
| SCHEMBL216748 | 0.68 | EGLN1 (0.44) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | claimed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | SCD 1/4885PTGDR2 1167/4885KDR 2293/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | SCD 1/4885PTGDR2 1167/4885KDR 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.